Last updated on June 2020

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-na ve GBM Patients.


Brief description of study

A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-nave patients after resection of glioblastoma.

Detailed Study Description

This clinical trail includes two phases: basic treatment phase and immunotherapy phase. In basic treatment phase, patients will receive concomitant radiation and TMZ-chemotherapy. In immunotherapy phase, besides maintenance chemotherapy with TMZ, Fusion cells will be administered with IL-12 to enhance the immunity of patients.

Clinical Study Identifier: NCT04388033

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.